Elguero Sonia, Wyman Allison, Hurd William W, Barker Nichole, Patel Bansari, Liu James H
Division of Reproductive Endocrinology & Infertility, Department of Obstetrics & Gynecology, University Hospitals Case Medical Center , Cleveland, OH , USA and.
Gynecol Endocrinol. 2015 Mar;31(3):229-32. doi: 10.3109/09513590.2014.981803. Epub 2014 Nov 28.
To investigate the effect of empiric use of luteal phase progesterone supplementation to improve endometrial receptivity in women undergoing treatment with clomiphene citrate in combination with intrauterine insemination (CC-IUI).
Retrospective cohort analysis.
University fertility center.
426 CC-IUI cycles from 292 patients with unexplained infertility.
Patients were treated with micronized intravaginal progesterone 100 mg twice daily beginning approximately three days after CC-IUI.
MAIN OUTCOME MEASURE(S): Clinical pregnancy per initiated cycle as defined by presence of fetal heart rate on ultrasound.
Clinical pregnancy rate was higher in patients receiving luteal phase support compared to patients not receiving luteal phase support (odds ratio: 2.04; 95% confidence interval: 1.01-4.14) after adjusting for all factors in the analysis using a multivariate logistic regression model. Age at the start of the cycle, BMI and CC dose were not shown to have an effect on clinical pregnancy rates. Patients with endometrial lining (EML) thickness 6-8 mm and >8 mm had increased clinical pregnancy rates compared to EML <6 mm independent of luteal phase progesterone use. Patients who appear to receive the greatest benefit of progesterone supplementation are in the 6-8 mm EML cohort.
Luteal phase progesterone supplementation in CC-IUI cycles can improve endometrial receptivity as judged by the improved clinical pregnancy rates as the primary outcome.
探讨在接受枸橼酸氯米芬联合宫腔内人工授精(CC-IUI)治疗的女性中,经验性使用黄体期孕激素补充剂以改善子宫内膜容受性的效果。
回顾性队列分析。
大学附属生育中心。
来自292例不明原因不孕症患者的426个CC-IUI周期。
患者在CC-IUI后约三天开始,每日两次经阴道给予100毫克微粒化黄体酮。
根据超声检查发现胎心来定义每个起始周期的临床妊娠情况。
在使用多因素逻辑回归模型对分析中的所有因素进行校正后,接受黄体期支持的患者的临床妊娠率高于未接受黄体期支持的患者(优势比:2.04;95%置信区间:1.01-4.14)。周期开始时的年龄、体重指数和氯米芬剂量对临床妊娠率无影响。与子宫内膜厚度(EML)<6毫米的患者相比,EML厚度为6-8毫米和>8毫米的患者临床妊娠率增加,且与黄体期使用黄体酮无关。似乎从黄体酮补充中获益最大的患者是EML在6-8毫米队列中的患者。
CC-IUI周期中补充黄体期孕激素可改善子宫内膜容受性,以临床妊娠率提高作为主要结局指标来判断。